Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosis.
Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosis.
复制标题
DOI：
10.1371/journal.pone.0171957
复制
发表时间：
2017
期刊：
影响因子：
3.7
通讯作者：
Kuroda M
中科院分区：
文献类型：
--
作者：
Yamada Y;Takanashi M;Sudo K;Ueda S;Ohno SI;Kuroda M
MicroRNA 29 b（miR-29 b）替代疗法可有效抑制小鼠模型中的纤维化。然而，为了开发miRNA模拟物的临床应用，必须解决核酸药物的副作用。在这项研究中，我们专注于miRNA模拟物，以开发特发性肺纤维化的治疗方法。我们开发了一种称为“miR-29 b Psh-match”的单链RNA，其具有独特的结构，以避免与miRNA的治疗用途相关的问题。miR-29 b Psh匹配和双链miR-29 b模拟物的比较表明，根据体内和体外实验，单链形式对纤维化显著有效。这种新形式的miR-29 b可能成为开发有效的肺纤维化治疗药物的基础。
MicroRNA 29b (miR-29b) replacement therapy is effective for suppressing fibrosis in a mouse model. However, to develop clinical applications for miRNA mimics, the side effects of nucleic acid drugs have to be addressed. In this study, we focused on miRNA mimics in order to develop therapies for idiopathic pulmonary fibrosis. We developed a single-stranded RNA, termed “miR-29b Psh-match,” that has a unique structure to avoid problems associated with the therapeutic uses of miRNAs. A comparison of miR-29b Psh-match and double-stranded one, termed “miR-29b mimic” indicated that the single-stranded form was significantly effective towards fibrosis according to both in vivo and in vitro experiments. This novel form of miR-29b may become the foundation for developing an effective therapeutic drug for pulmonary fibrosis.